An observational pilot study to evaluate the feasibility and quality of oncological home-hospitalization.


Journal

European journal of oncology nursing : the official journal of European Oncology Nursing Society
ISSN: 1532-2122
Titre abrégé: Eur J Oncol Nurs
Pays: Scotland
ID NLM: 100885136

Informations de publication

Date de publication:
Jun 2019
Historique:
received: 16 05 2018
revised: 13 03 2019
accepted: 19 03 2019
entrez: 24 6 2019
pubmed: 24 6 2019
medline: 20 9 2019
Statut: ppublish

Résumé

The objective of this pilot study was to evaluate the feasibility of oncological home-hospitalization and to compare its quality with standard ambulatory hospital care in terms of patient-reported quality of life and related endpoints by means of a set of validated patient-reported outcome measures (PROMs). An observational cohort study (clinicaltrials.gov identifier: NCT03073499) was conducted, allocating patients to (partial) home-hospitalization or standard ambulatory hospital care. PROMs were completed by both cohorts at start of treatment and eight weeks later. An additional study-specific questionnaire was presented to the intervention cohort at study-end assessing their satisfaction with and preferences for the provided homecare. Thirty patients received home-hospitalization, corresponding to 116 interventions. For twenty-eight patients, this comprised all assessments required prior to administration of treatment, which resulted in a significant reduction of waiting time for treatment administration at the hospital in comparison with the control cohort (n = 24) (average reduction of 1:12 h, p < 0.001). Two patients received actual subcutaneous therapy at home. None of the PROM's evaluated revealed significant differences between both cohorts (all p > 0.05). 29/30 patients of the intervention cohort were satisfied with the provided homecare and preferred to have it continued, 22/25 patients declared to feel at home at least as safe as in the hospital. No serious safety concerns were reported. The results of this pilot study suggest that (partial) oncological home-hospitalization is feasible, safe and statistically not affecting patient-reported quality of life. Furthermore, this care model was acceptable and preferred by a substantial number of cancer patients.

Identifiants

pubmed: 31229206
pii: S1462-3889(19)30040-7
doi: 10.1016/j.ejon.2019.03.003
pii:
doi:

Banques de données

ClinicalTrials.gov
['NCT03073499']

Types de publication

Controlled Clinical Trial Journal Article Observational Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

44-52

Informations de copyright

Copyright © 2019. Published by Elsevier Ltd.

Auteurs

Lieselot Cool (L)

Cancer Centre, General Hospital Groeninge, Pres. Kennedylaan 4, 8500, Kortrijk, Belgium; Faculty of Medicine and Health Sciences, Ghent University, De Pintelaan 185, 3K3, 9000, Gent, Belgium. Electronic address: lieselot.cool@azgroeninge.be.

Jana Missiaen (J)

Cancer Centre, General Hospital Groeninge, Pres. Kennedylaan 4, 8500, Kortrijk, Belgium. Electronic address: jana.missiaen@azgroeninge.be.

Dominique Vandijck (D)

Faculty of Medicine and Health Sciences, Ghent University, De Pintelaan 185, 3K3, 9000, Gent, Belgium. Electronic address: dominique.vandijck@ugent.be.

Tessa Lefebvre (T)

Cancer Centre, General Hospital Groeninge, Pres. Kennedylaan 4, 8500, Kortrijk, Belgium. Electronic address: tessa.lefebvre@azgroeninge.be.

Michelle Lycke (M)

Cancer Centre, General Hospital Groeninge, Pres. Kennedylaan 4, 8500, Kortrijk, Belgium. Electronic address: michelle.lycke@azgroeninge.be.

Pieter Jan De Jonghe (PJ)

Hospital Pharmacy, General Hospital Groeninge, Pres. Kennedylaan 4, 8500, Kortrijk, Belgium. Electronic address: pieterjan.dejonghe@azgroeninge.be.

Philippe Vergauwe (P)

Cancer Centre, General Hospital Groeninge, Pres. Kennedylaan 4, 8500, Kortrijk, Belgium. Electronic address: philippe.vergauwe@azgroeninge.be.

Veerle Foulon (V)

Department of Pharmaceutical and Pharmacological Sciences, Catholic University Leuven, O&N II, Herestraat 49, 3000, Leuven, Belgium. Electronic address: veerle.foulon@kuleuven.be.

Hans Pottel (H)

Department of Public Health and Primary Care @ Kulak, Catholic University Leuven, Kulak Etienne Sabbelaan 53, 8500, Kortrijk, Belgium. Electronic address: hans.pottel@kuleuven.be.

Philip Debruyne (P)

Cancer Centre, General Hospital Groeninge, Pres. Kennedylaan 4, 8500, Kortrijk, Belgium; Faculty of Health, Social Care and Education, Anglia Ruskin University, Bishop Hall Lane, Chelmsford, CM1 1SQ, UK. Electronic address: philip.debruyne@azgroeninge.be.

Koen Van Eygen (K)

Cancer Centre, General Hospital Groeninge, Pres. Kennedylaan 4, 8500, Kortrijk, Belgium. Electronic address: koen.vaneygen@azgroeninge.be.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH